ValiRx Plc (VAL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The companys products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE BCL-2, and NAV3 cancer screening test. It uses GeneICE technology, which enables silencing of specific genes by targeted histone deacetylation for chromatin condensation. ValiRxs ValiMedix division sells and distributes oncology therapeutics. The companys ValiPharma division is a therapeutics division that provides technologies for the treatment of cancer. Itss ValiFinn division offers research and development services. The company also develops clinical trials, which is used to treat hormone induced refractory prostate cancer and other conditions of hormone. ValiRx is headquartered in London, the UK.

ValiRx Plc (VAL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ValiRx Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ValiRx Plc, Medical Devices Deals, 2012 to YTD 2018 10
ValiRx Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ValiRx Plc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
ValiRx Acquires TRAC Biomarker Technology for USD1 Million 12
Partnerships 13
ValiRx Enters into Co-Development Agreement with Pharmatest Services 13
ValiRx Enters into Agreement with German Cancer Research Center for VAL-101 14
ValiRx Forms Joint Venture With Tangent Reprofiling 15
Licensing Agreements 16
Mystic Pharma Enters into Licensing Agreement with ValiRx 16
Equity Offering 17
ValiRx Raises USD1.33 Million in Private Placement of Shares 17
ValiRx Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 18
ValiRx Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 19
ValiRx Raises USD1.3 Million in Public Offering of Shares 20
ValiRx Raises USD0.7 Million in Private Placement of Shares 21
Valirx Raises Funds in Private Placement of Shares 22
Valirx Raises USD1.4 Million in Private Placement of Shares 23
Valirx Raises USD1.58 Million in Placing of Ordinary Shares 24
ValiRx Raises USD0.7 Million in Private Placement of Shares 25
ValiRx Raises USD3.8 Million in Private Placement of Shares 26
ValiRx Raises USD1.2 Million in Private Placement of Shares 27
ValiRx Completes Private Placement of Shares for USD1.3 Million 28
ValiRx Completes Private Placement Of Shares For US$4.75 Million 29
ValiRx Completes Private Placement Of Shares For US$1.6 Million 30
ValiRx Completes Private Placement Of Shares For 1.4 Million 31
Acquisition 32
Sovicell Science for Life Acquires ValiRx (Finland) from Valirx 32
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 33
ValiRx Plc - Key Competitors 34
ValiRx Plc - Key Employees 35
ValiRx Plc - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 36
Recent Developments 37
Financial Announcements 37
Apr 10, 2018: ValiRx: Final Results for the Year Ended 31 December 2017 37
Sep 26, 2017: Valirx: Half Yearly Report For The Period Ended 30 June 2017 41
May 05, 2017: ValiRx: Final Results for the Year Ended 31 December 2016 43
Other Significant Developments 46
Apr 18, 2017: ValiRx: Change of Registered Office 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List Of Tables

List of Tables
ValiRx Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ValiRx Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ValiRx Plc, Deals By Therapy Area, 2012 to YTD 2018 9
ValiRx Plc, Medical Devices Deals, 2012 to YTD 2018 10
ValiRx Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ValiRx Acquires TRAC Biomarker Technology for USD1 Million 12
ValiRx Enters into Co-Development Agreement with Pharmatest Services 13
ValiRx Enters into Agreement with German Cancer Research Center for VAL-101 14
ValiRx Forms Joint Venture With Tangent Reprofiling 15
Mystic Pharma Enters into Licensing Agreement with ValiRx 16
ValiRx Raises USD1.33 Million in Private Placement of Shares 17
ValiRx Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 18
ValiRx Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 19
ValiRx Raises USD1.3 Million in Public Offering of Shares 20
ValiRx Raises USD0.7 Million in Private Placement of Shares 21
Valirx Raises Funds in Private Placement of Shares 22
Valirx Raises USD1.4 Million in Private Placement of Shares 23
Valirx Raises USD1.58 Million in Placing of Ordinary Shares 24
ValiRx Raises USD0.7 Million in Private Placement of Shares 25
ValiRx Raises USD3.8 Million in Private Placement of Shares 26
ValiRx Raises USD1.2 Million in Private Placement of Shares 27
ValiRx Completes Private Placement of Shares for USD1.3 Million 28
ValiRx Completes Private Placement Of Shares For US$4.75 Million 29
ValiRx Completes Private Placement Of Shares For US$1.6 Million 30
ValiRx Completes Private Placement Of Shares For 1.4 Million 31
Sovicell Science for Life Acquires ValiRx (Finland) from Valirx 32
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 33
ValiRx Plc, Key Competitors 34
ValiRx Plc, Key Employees 35
ValiRx Plc, Subsidiaries 36
ValiRx Plc, Joint Venture 36

List Of Figures

List of Figures
ValiRx Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ValiRx Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ValiRx Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ValiRx Plc, Medical Devices Deals, 2012 to YTD 2018 10

ValiRx Plc (VAL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The companys products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE BCL-2, and

USD 250 View Report

VALIRX PLC Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

VALIRX PLC Company Profile is a detailed strategic and analytical report on VALIRX PLC. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Valaris Plc (VAL) - Financial and Strategic SWOT Analysis Review

Valaris Plc (VAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125 View Report

VALIRX PLC Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

VALIRX PLC Company Profile is a detailed strategic and analytical report on VALIRX PLC. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available